Transplants From Unrelated Donors

Download as pptx, pdf, or txt
Download as pptx, pdf, or txt
You are on page 1of 8

Transplants from Unrelated Donors

• Cord blood from unrelated donors has become an


important source of hematopoietic stem cells (HSCs).
• The donor-recipient HLA mismatch level affects the
outcome of unrelated cord blood transplantation. 
• Possible permissive mismatches involve the relationship
between direction HLA mismatch vector or direction and
transplantation outcomes.
• In most cord blood transplants, a mismatched HLA
antigen is present in recipient and donor. This type of
mismatch is bidirectional between the graft and host.
Two main pathways of T-cell
regeneration
• Thymopoiesis and peripheral blood expansion of mature
T cells. 
• Thymopoiesis provides a new pool of naïve T cells that
is essential for sustained long-term immunity.
• Secondary cytopenia is a common complication of stem
cell transplantation. 
• Causes of secondary cytopenia include viral infection,
septicemia, GVHD, and myelotoxicdrugs.
Current Directions
• Consists of direct reprogramming of skin cells to
a multipotent progenitor stage by the introduction of a
single transcription factor, Oct4.
• Another potential game-changing advancement would
be the ability to reprogram human adult stem cells to
an expandable condition without reducing the long-
term self renewal properties and their safety. 
• The general goal of this field is transplanting donor
stem cells to replace or repair defective cells in a
patient.
There are two critical concerns in
the transplantation of umbilical cord
blood:
• 1. Initial time to engraftment 
2. Restoration of immune function
• The initial engraftment of cells that develop into the
myeloid cell line (red blood cells, platelets, and
granulocyte/monocyte) is 1 month. 
• Development of T- and B-lymphocytes commonly takes
6 months or more after transplantation.
Two factors have been found to be
of extreme importance:
• 1.The total dose of progenitor (CD34+) cells in a cord
blood unit has been associated with patient survival
• 2.The total dose of clonogenic progenitors with the graft
correlates with engraftment of the transplant.
• To transplant stem cells into a fetus early in gestation.
The benefit is that in utero transplantation would occur
when the immune system of the fetus is immature,
which would provide the theoretical opportunity to
induce fetal tolerance of foreign cells. 
• This would avoid rejection and the need for
immunosuppressive therapy.

You might also like